Parents have been warned of the negative effects of too much screen time for their babies. A new study found that infants exposed to computer, TV and phone screens for hours could suffer lower cognitive skills later in life.  In a study titled “Associations Between Infant Screen Use, Electroencephalography, Markers and Cognitive Outcomes,” published Monday
0 Comments
Here are 3 tips to help you achieve superhuman productivity. Number one, be respectful of your time. Time is our most valuable asset, yet most of us don’t treat it as such. Although I can’t tell you exactly how you should spend your time, make sure it aligns with your priorities and life goals. Number
0 Comments
Running does not appear to cause sustained wear and tear of healthy knee cartilage, with research suggesting that the small, short-term changes to cartilage after a run reverse within hours. A systematic review and meta-analysis published in the most recent issue of Osteoarthritis and Cartilage presents the findings involving 396 adults, which compared the “before”
0 Comments
Whatever route we explore to achieve it, and whatever unique barriers we face, there is a unifying desire that connects us all: to nurture our wellbeing In my time doing this job, I’ve sat down with a lot of different people. I’ve chatted with global superstars, actors, singers, and models. But also, artists, activists, authors,
0 Comments
Researchers have found that a focused ultrasound technique, known as sonobiopsy, can release more neurodegenerative disorder biomarkers in the blood to ease the diagnosis of the diseases. The study, published Tuesday in the journal Radiology, found a non-invasive method to detect biomarkers in blood that were previously restricted by the blood-brain barrier. Focused-ultrasound-mediated liquid biopsy
0 Comments
Can a Virtual Assistant Help People With Diabetes and Depression? – Diabetes Daily Learning Center Learning Center: LearningCenter Diabetes Daily does not provide medical advice,diagnosis or treatment.Get additional information.© 2005 – 2023 Everyday Health, Inc., a Ziff Davis company. Everyday Health is among the federally registered trademarks of Everyday Health, Inc. and may not be
0 Comments
Functions like sensing and pacing in implantable cardioverter defibrillators (ICD) tend to resist interference from the energy fields generated by MRI, as long as device programming is properly adjusted before the scan. That applies even to patients with older “legacy” devices implanted before the 2015 advent of MRI-conditional ICDs despite, in practice, prevalent but misguided
0 Comments
SAN DIEGO and TORONTO, Jan. 30, 2023. Aptose Biosciences Inc. (“Aptose”) today announced the 120 mg monotherapy dosing of patients in the APTIVATE Phase 1/2 clinical trial of tuspetinib (formerly HM43239), an oral, mutation agnostic tyrosine kinase inhibitor (TKI) being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia (R/R AML).
0 Comments
Vials and a medical syringe seen displayed in front of the Food and Drug Administration (FDA) of the United States logo. FDA finds the COVID-19 vaccine. Pavlo Gonchar | LightRocket | Getty Images The Food and Drug Administration on Tuesday said its emergency authorizations of Covid vaccines, tests and treatments will not be impacted by
0 Comments
olorofim Treatment for Fungal Infections F2G Announces FDA Filing Acceptance Of New Drug Application For Olorofim For The Treatment Of Invasive Fungal Infections PRINCETON, N.J., Dec. 19, 2022 (GLOBE NEWSWIRE) — F2G Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its New Drug Application (NDA) for olorofim for
0 Comments
aprocitentan Treatment for High Blood Pressure Idorsia Submits a New Drug Application to the US FDA for Aprocitentan for the Treatment of Patients with Difficult-to-Control Hypertension The application includes data from the Phase 3 registration study of patients with resistant hypertension, where aprocitentan demonstrated a sustained blood pressure reduction over 48 weeks and was well-tolerated
0 Comments
Treatment for Geographic Atrophy Iveric Bio Announces Completion of Rolling NDA Submission to FDA for Avacincaptad Pegol for the Treatment of Geographic Atrophy PARSIPPANY, N.J.–(BUSINESS WIRE)–Dec. 20, 2022– IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it has submitted to the U.S. Food and Drug Administration (FDA) the third and final part of its New
0 Comments
etrasimod Treatment for Ulcerative Colitis Pfizer Announces FDA and EMA Acceptance of Etrasimod Regulatory Submissions for Ulcerative Colitis Filings based on two Phase 3 trials demonstrating significant clinical remission versus placebo and safety profile consistent with previous studies NEW YORK–(BUSINESS WIRE) December 21, 2022 — Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food
0 Comments
Saint-Herblain (France), December 23, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces that it has completed rolling submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its single-shot chikungunya vaccine candidate, VLA1553. Valneva is seeking approval of its investigational chikungunya vaccine
0 Comments
palovarotene Treatment for Fibrodysplasia Ossificans Progressiva Ipsen Receives Complete Response Letter for Palovarotene, an Investigational Treatment for Fibrodysplasia Ossificans Progressiva The CRL is related to the U.S. FDA’s previous request for additional information on palovarotene clinical trial data Ipsen anticipates responding to the request in the first quarter of 2023 PARIS, FRANCE, 23 December 2022
0 Comments
roluperidone Treatment for Schizophrenia Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia BURLINGTON, Mass., Dec. 28, 2022 (GLOBE NEWSWIRE) — Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today
0 Comments
vonoprazan Treatment for Erosive Esophagitis Phathom Pharmaceuticals Provides Update on New Drug Application Review of Vonoprazan for Erosive Esophagitis FLORHAM PARK, N.J., Jan. 03, 2023 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, today announced that the U.S. Food and
0 Comments
nirsevimab Treatment for Respiratory Syncytial Virus Nirsevimab US Regulatory Submission Accepted for the Prevention of RSV Lower Respiratory Tract Disease in Infants and Children up to Age 24 Months 5 January 2023 — Nirsevimab is being developed and commercialised by AstraZeneca in collaboration with Sanofi and is the first single-dose preventative option for the broad
0 Comments
vamorolone Treatment for Duchenne Muscular Dystrophy Santhera and ReveraGen Announce FDA Acceptance of New Drug Application for Vamorolone in Duchenne Muscular Dystrophy Pratteln, Switzerland, and Rockville, MD, USA, January 9, 2023 – Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce that the U.S. Food and Drug Administration (FDA) has accepted the new drug application
0 Comments
FDA Approves Leqembi (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer’s Disease Accelerated Approval is based on Phase 2 data showing a reduction in amyloid-beta plaques in early AD patients treated with Leqembi™ Treatment with Leqembi should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the
0 Comments
FDA Approves Airsupra (albuterol/budesonide) Metered-Dose Inhaler to Reduce the Risk of Asthma Exacerbations January 11, 2023 — Airsupra (albuterol/budesonide), formerly known as PT027, has been approved in the US for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and older. The approval
0 Comments
People living with type 2 diabetes can now take Rybelsus®, the first and only oral glucagon-like peptide-1 (GLP-1) analog, along with diet and exercise, as initial therapy to help lower their A1C1,2 Since its approval, Rybelsus® has been prescribed to hundreds of thousands of patients to help improve glycemic control along with diet and exercise3
0 Comments
FDA Approves Rykindo (risperidone) Extended-Release Injectable Suspension for the Treatment of Schizophrenia and Bipolar 1 Disorder PRINCETON, N.J., Jan. 15, 2023 /PRNewswire/ — Luye Pharma Group (Luye Pharma), an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications, today announced that the U.S. Food and Drug Administration (FDA) has approved Rykindo
0 Comments